Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prometheus Biosciences, Inc. - Common Stock (NQ: RXDX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 15, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prometheus Biosciences, Inc. - Common Stock

RXDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Prometheus Biosciences, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
From Kahn Swick & Foti, LLC
Via Business Wire
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
- Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 - 
From Prometheus Biosciences
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
North America Could Possibly Emerge as the Market Leader for Billion Dollar Detox Drinks Industry
EQNX::TICKER_START (NASDAQ:CELH),(NASDAQ:OMER),(NYSE:MRK),(NASDAQ:RXDX) EQNX::TICKER_END 
Via FinancialNewsMedia
RXDX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Prometheus Biosciences, Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
From Prometheus Biosciences
Via GlobeNewswire
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Prometheus Biosciences
Via GlobeNewswire
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
From Prometheus Biosciences
Via GlobeNewswire
Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)
From Prometheus Biosciences
Via GlobeNewswire
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
From Prometheus Biosciences
Via GlobeNewswire
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Prometheus Biosciences
Via GlobeNewswire
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
From Prometheus Biosciences
Via GlobeNewswire
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
From Prometheus Biosciences
Via GlobeNewswire
Prometheus Biosciences (NASDAQ: RXDX) Reports PRA023 Candidate Achieved Positive Results in Both its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Clinical Trials
Prometheus Biosciences, Inc. (NASDAQ: RXDX) is engaged as a clinical-stage biotechnology company, which is focused on the research, development and 
Via Spotlight Growth
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
From Prometheus Biosciences
Via GlobeNewswire
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
From Prometheus Biosciences
Via GlobeNewswire
Prometheus Biosciences to Participate at November Healthcare Conferences
From Prometheus Biosciences
Via GlobeNewswire
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052
From Prometheus Biosciences
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS